LRRC25 and urinary bladder cancer: In bladder cancer, intravesical P-MAPA immunotherapy promoted a distinct activation of the TLR2- and TLR4-mediated innate immune system, resulting in increased IFN-γ signaling (TRIF-dependent pathway), which was more effective in the treatment of this tumor [15].